Abstract
Background: Falls are common in Parkinson's disease so any intervention that reduced falls risk would be of value. One potential intervention is the use of cholinesterase inhibitor (ChEi) drugs. Objective: To establish the minimum clinically important difference (MCID) for fall rates to inform the effect estimate for sample size calculations of future clinical trials. Methods: We performed a Delphi study assembling a panel of experts in Parkinson's disease from academic and clinical medicine in order to reach a consensus of opinion. Responses from a panel were summarised and resent to the group, until consensus was reached. Results: 780 clinicians, who had been caring for people with Parkinson's for an average of 14 years, were contacted via three routes. The median (Interquartile range (IQR)) MCID after round 1 was 25% (IQR 20–30%) which equates to the prevention of 5 (IQR 4–6) falls per year. Increasing consensus after round two confirmed the MCID of 25%, narrowing the (IQ) range to 20%–25%. This was unchanged when the panel were shown the number of participants that would need to be recruited to a clinical trial in order to achieve this difference. Conclusions: We have established that an expert panel of PD specialists consider that an intervention that demonstrated a 25% (IQR 20–25%) relative reduction in falls rate would be clinically meaningful. This estimate can be used to help determine the sample size for any future clinical trial.
Original language | English |
---|---|
Pages (from-to) | 106-110 |
Number of pages | 5 |
Journal | Parkinsonism and Related Disorders |
Volume | 61 |
Early online date | 8 Nov 2018 |
DOIs | |
Publication status | Published - 1 Apr 2019 |
Research Groups and Themes
- BTC (Bristol Trials Centre)
- BRTC
- Ageing and Movement Research Group
Keywords
- Parkinson disease
- Delphi technique
- Falls
- Cholinesterase inhibitors
- Sample size
Fingerprint
Dive into the research topics of 'The minimum clinically important difference (MCID) for a falls intervention in Parkinson's: A delphi study'. Together they form a unique fingerprint.Profiles
-
Professor Emily J Henderson
- Bristol Medical School (PHS) - Professor of Ageing and Movement Disorders
- Bristol Population Health Science Institute
- Bristol Neuroscience
Person: Academic , Member